US20150166654A1 - Target tissue-specific antigen-binding molecule - Google Patents

Target tissue-specific antigen-binding molecule Download PDF

Info

Publication number
US20150166654A1
US20150166654A1 US14/402,574 US201314402574A US2015166654A1 US 20150166654 A1 US20150166654 A1 US 20150166654A1 US 201314402574 A US201314402574 A US 201314402574A US 2015166654 A1 US2015166654 A1 US 2015166654A1
Authority
US
United States
Prior art keywords
amino acid
antigen
thr
tyr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/402,574
Other languages
English (en)
Inventor
Tomoyuki Igawa
Shigero Tamba
Kanako Tatsumi
Shun Shimizu
Shojiro Kadono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Assigned to CHUGAI SEIYAKU KABUSHIKI KAISHA reassignment CHUGAI SEIYAKU KABUSHIKI KAISHA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KADONO, SHOJIRO, TAMBA, Shigero, IGAWA, TOMOYUKI, TATSUMI, Kanako, SHIMIZU, SHUN
Publication of US20150166654A1 publication Critical patent/US20150166654A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
US14/402,574 2012-05-30 2013-05-30 Target tissue-specific antigen-binding molecule Abandoned US20150166654A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012-123781 2012-05-30
JP2012123781 2012-05-30
JP2012-177311 2012-08-09
JP2012177311 2012-08-09
PCT/JP2013/064975 WO2013180200A1 (ja) 2012-05-30 2013-05-30 標的組織特異的抗原結合分子

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/064975 A-371-Of-International WO2013180200A1 (ja) 2012-05-30 2013-05-30 標的組織特異的抗原結合分子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/539,765 Division US11673947B2 (en) 2012-05-30 2019-08-13 Target tissue-specific antigen-binding molecule

Publications (1)

Publication Number Publication Date
US20150166654A1 true US20150166654A1 (en) 2015-06-18

Family

ID=49673387

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/402,574 Abandoned US20150166654A1 (en) 2012-05-30 2013-05-30 Target tissue-specific antigen-binding molecule
US16/539,765 Active 2034-02-03 US11673947B2 (en) 2012-05-30 2019-08-13 Target tissue-specific antigen-binding molecule
US18/138,888 Pending US20230279099A1 (en) 2012-05-30 2023-04-25 Target tissue-specific antigen-binding molecule

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/539,765 Active 2034-02-03 US11673947B2 (en) 2012-05-30 2019-08-13 Target tissue-specific antigen-binding molecule
US18/138,888 Pending US20230279099A1 (en) 2012-05-30 2023-04-25 Target tissue-specific antigen-binding molecule

Country Status (14)

Country Link
US (3) US20150166654A1 (ja)
EP (2) EP3795215A1 (ja)
JP (6) JPWO2013180200A1 (ja)
KR (3) KR102413947B1 (ja)
CN (3) CN107759686A (ja)
AU (4) AU2013268418B2 (ja)
CA (1) CA2874721A1 (ja)
DK (1) DK2857420T3 (ja)
HK (3) HK1205149A1 (ja)
MX (2) MX2014014678A (ja)
RU (1) RU2743463C2 (ja)
SG (2) SG10202006507XA (ja)
TW (3) TWI797443B (ja)
WO (1) WO2013180200A1 (ja)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160039912A1 (en) * 2013-04-02 2016-02-11 Chugai Seiyaku Kabushiki Kaisha Fc REGION VARIANT
US20160130347A1 (en) * 2012-10-08 2016-05-12 Roche Glycart Ag Fc-free antibodies comprising two Fab-fragments and methods of use
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
WO2018148566A1 (en) * 2017-02-10 2018-08-16 Adimab, Llc Proteins binding bcma, nkg2d and cd16
WO2018210795A1 (en) * 2017-05-16 2018-11-22 Synthon Biopharmaceuticals B.V. ANTI-SIRPα ANTIBODIES
US20180346605A1 (en) * 2017-06-05 2018-12-06 Janssen Biotech, Inc. Engineered Multispecific Antibodies and Other Multimeric Proteins with Asymmetrical CH2-CH3 Region Mutations
US10253100B2 (en) 2011-09-30 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
CN110082536A (zh) * 2019-04-17 2019-08-02 广州医科大学附属肿瘤医院 一种乳腺癌细胞标志物细胞因子群及其应用
US10377833B2 (en) * 2016-07-22 2019-08-13 Beijing Mabworks Biotech Co., Ltd. Bispecific anti-HER2 antibody
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
US10556949B2 (en) 2011-09-30 2020-02-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
US10618965B2 (en) 2011-02-25 2020-04-14 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
US10738111B2 (en) 2014-12-19 2020-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
US10961530B2 (en) 2013-12-04 2021-03-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US11091539B2 (en) 2016-07-08 2021-08-17 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
US11142563B2 (en) 2012-06-14 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified Fc region
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
US11242381B2 (en) 2017-04-21 2022-02-08 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
US11248041B2 (en) 2017-10-31 2022-02-15 Staten Biotechnology B.V. Anti-ApoC3 antibodies
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11639394B2 (en) 2017-03-29 2023-05-02 Hoffmann-La Roche Inc. Bispecific antigen binding molecule for a costimulatory TNF receptor
US11639397B2 (en) 2011-08-23 2023-05-02 Roche Glycart Ag Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use
US11673947B2 (en) 2012-05-30 2023-06-13 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
US11820793B2 (en) 2011-11-30 2023-11-21 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
US11827699B2 (en) 2011-09-30 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11858980B2 (en) 2016-08-02 2024-01-02 Visterra, Inc. Engineered polypeptides and uses thereof
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11938194B2 (en) 2017-02-28 2024-03-26 Seagen Inc. Cysteine mutated antibodies for conjugation

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
CN113307873A (zh) 2013-11-11 2021-08-27 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
SG10201914109VA (en) * 2015-08-11 2020-02-27 Wuxi Biologics Cayman Inc Novel anti-pd-1 antibodies
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
US20200399373A1 (en) 2018-02-14 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule and combination
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
SG11202101152QA (en) 2018-08-03 2021-03-30 Chugai Pharmaceutical Co Ltd Antigen-binding molecule containing two antigen-binding domains that are linked to each other
KR102259473B1 (ko) * 2018-08-10 2021-06-02 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
CN111683681B (zh) * 2018-09-25 2023-03-24 信达生物制药(苏州)有限公司 包含抗ox40抗体的制剂、其制备方法及其用途
CR20210467A (es) * 2019-03-14 2021-10-07 Genentech Inc Tratamiento de cáncer con anticuerpos biespecíficos contra her2xcd3 en combinación con mab anti-her2
EP3943108A4 (en) * 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
MX2021012251A (es) 2019-04-10 2021-11-12 Chugai Pharmaceutical Co Ltd Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc).
BR112021019571A2 (pt) 2019-04-19 2021-12-07 Chugai Pharmaceutical Co Ltd Receptor quimérico que reconhece o sítio de modificação do anticorpo
CN114867532A (zh) 2019-12-18 2022-08-05 豪夫迈·罗氏有限公司 双特异性抗ccl2抗体
WO2021131021A1 (ja) * 2019-12-27 2021-07-01 中外製薬株式会社 抗ｃｔｌａ－４抗体およびその使用
CA3168510A1 (en) 2020-02-05 2021-08-12 Chugai Seiyaku Kabushiki Kaisha Methods for producing and/or enriching recombinant antigen-binding molecules
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
CN115397866A (zh) 2020-03-31 2022-11-25 中外制药株式会社 靶向dll3的多特异性抗原结合分子及其用途
WO2022044248A1 (ja) 2020-08-28 2022-03-03 中外製薬株式会社 ヘテロ二量体Ｆｃポリペプチド
KR20240021859A (ko) 2021-06-18 2024-02-19 에프. 호프만-라 로슈 아게 이중특이적 항-ccl2 항체
CR20240026A (es) 2021-06-25 2024-03-14 Chugai Seiyaku Kk Anticuerpo anti-ctla-4
KR20240024255A (ko) 2021-06-25 2024-02-23 추가이 세이야쿠 가부시키가이샤 항ctla-4 항체의 사용

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141456A1 (en) * 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
WO2008092117A2 (en) * 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
US20080292637A1 (en) * 2005-11-30 2008-11-27 Pnina Fishman Therapeutic Uses of A3 Adenosine Receptor Antibodies
WO2009086320A1 (en) * 2007-12-26 2009-07-09 Xencor, Inc Fc variants with altered binding to fcrn

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE69620898T2 (de) 1995-09-01 2002-11-07 Univ Washington Seattle Interaktive molekulare konjugate
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
AU784151B2 (en) 1999-12-28 2006-02-09 Ribonomics, Inc. Methods for isolating and characterizing endogenous mRNA-protein (mRNP) complexes
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
CA2785941C (en) 2000-10-06 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
WO2002079255A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
JP4281869B2 (ja) 2001-06-22 2009-06-17 中外製薬株式会社 抗グリピカン３抗体を含む細胞増殖抑制剤
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
JP3991280B2 (ja) 2002-06-05 2007-10-17 中外製薬株式会社 抗体作製方法
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
NZ541503A (en) 2003-01-22 2008-09-26 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
JP2005292087A (ja) 2004-04-05 2005-10-20 Shionogi & Co Ltd ５’−デオキシ−５’−メチルチオアデノシンに対する抗体
KR20070038453A (ko) 2004-04-16 2007-04-10 마크로제닉스, 인크. ＦｃγＲＩＩＢ-특이적 항체 및 그의 사용 방법
NZ579543A (en) 2004-07-09 2011-07-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
DK1776384T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
CA2577370A1 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
RU2412200C2 (ru) * 2004-11-12 2011-02-20 Ксенкор, Инк. Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn
DK1817340T3 (da) * 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2627890A1 (en) 2005-10-31 2007-05-10 The Government Of The United States As Represented By The Secretary Of H Ealth And Human Services, National Institutes Of Health Antibodies and immunotoxins that target human glycoprotein nmb
AU2007281284A1 (en) 2006-08-02 2008-02-07 The Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
CN103408661B (zh) 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US10457719B2 (en) * 2007-09-18 2019-10-29 The Jackson Laboratory Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
MX2010003099A (es) 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
EP4238993A3 (en) * 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8541178B2 (en) 2008-05-13 2013-09-24 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
CA2736277C (en) * 2008-09-10 2016-06-21 Philochem Ag Display library for antibody selection
EP2352521B1 (en) 2008-10-14 2020-09-16 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
US8647829B2 (en) 2009-02-20 2014-02-11 General Electric Company Switchable affinity binders
ES2661310T3 (es) 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
KR20120044294A (ko) 2009-05-01 2012-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP2011097869A (ja) * 2009-11-05 2011-05-19 Japan Science & Technology Agency 抗ヒトアデノシンＡ２ａ受容体モノクローナル抗体
JP2011184418A (ja) * 2010-03-11 2011-09-22 Tokyo Institute Of Technology 親和性可変抗体
CN102844332B (zh) 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
JP5480678B2 (ja) * 2010-03-12 2014-04-23 日立マクセル株式会社 磁気テープ装置、データ再生方法
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
JP6121904B2 (ja) 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR102147548B1 (ko) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
KR102366029B1 (ko) 2011-09-30 2022-02-23 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
TWI827333B (zh) 2011-09-30 2023-12-21 日商中外製藥股份有限公司 促進抗原消失的抗原結合分子
CA3186007A1 (en) 2011-09-30 2013-04-04 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
EP3517550A1 (en) 2011-11-30 2019-07-31 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
KR102219987B1 (ko) 2012-02-24 2021-02-25 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
JPWO2013180200A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 標的組織特異的抗原結合分子
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
TWI697501B (zh) 2012-08-24 2020-07-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
JP7060317B2 (ja) 2013-12-04 2022-04-26 中外製薬株式会社 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ
EP3156072B1 (en) 2014-06-11 2020-08-19 IDAC Theranostics, Inc. Method for reducing side effects of immune checkpoint control agent
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
SG11201607165YA (en) 2014-12-19 2016-09-29 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
ES2746340T3 (es) 2015-04-22 2020-03-05 Curevac Ag Composición que contiene ARN para el tratamiento de enfermedades tumorales
WO2016194992A1 (ja) 2015-06-05 2016-12-08 中外製薬株式会社 免疫活性化剤の併用
PE20181336A1 (es) 2015-09-18 2018-08-21 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
CA3006743A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
WO2017104783A1 (en) 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102259473B1 (ko) * 2018-08-10 2021-06-02 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
US20240002510A2 (en) 2021-06-25 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Anti-ctla-4 antibody and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141456A1 (en) * 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
US20080292637A1 (en) * 2005-11-30 2008-11-27 Pnina Fishman Therapeutic Uses of A3 Adenosine Receptor Antibodies
WO2008092117A2 (en) * 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2009086320A1 (en) * 2007-12-26 2009-07-09 Xencor, Inc Fc variants with altered binding to fcrn

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HogenEsch et al. J. Controlled Release 2012; 164:183-186 *
Hu et al., PNAS 107(14):6252-57 (2010) *
Lukashev et al. Cancer Metastasis Rev 2007; 26:273-79 *
Pedroza et al., (2011) PLoS ONE 6(7): e22667. doi:10.1371/journal.pone.0022667, pages 1-13 *
Richard et al., Int. J. Cancer 2006; 119:2044-53 *
Tang et al. Cancer Letters 2016; 370:85-90 *

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9890377B2 (en) 2008-04-11 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US10618965B2 (en) 2011-02-25 2020-04-14 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
US11718678B2 (en) 2011-02-25 2023-08-08 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
US11639397B2 (en) 2011-08-23 2023-05-02 Roche Glycart Ag Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use
US10253100B2 (en) 2011-09-30 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
US10556949B2 (en) 2011-09-30 2020-02-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
US11827699B2 (en) 2011-09-30 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
US11820793B2 (en) 2011-11-30 2023-11-21 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
US11673947B2 (en) 2012-05-30 2023-06-13 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
US11142563B2 (en) 2012-06-14 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified Fc region
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
US10087250B2 (en) * 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
US20160130347A1 (en) * 2012-10-08 2016-05-12 Roche Glycart Ag Fc-free antibodies comprising two Fab-fragments and methods of use
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US20160039912A1 (en) * 2013-04-02 2016-02-11 Chugai Seiyaku Kabushiki Kaisha Fc REGION VARIANT
US11267868B2 (en) * 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US10961530B2 (en) 2013-12-04 2021-03-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
US11912989B2 (en) 2013-12-04 2024-02-27 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
US10738111B2 (en) 2014-12-19 2020-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US11454633B2 (en) 2014-12-19 2022-09-27 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US10519229B2 (en) 2015-02-05 2019-12-31 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding IL-8 antibodies
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
US11180548B2 (en) 2015-02-05 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Methods of neutralizing IL-8 biological activity
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11091539B2 (en) 2016-07-08 2021-08-17 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
US10377833B2 (en) * 2016-07-22 2019-08-13 Beijing Mabworks Biotech Co., Ltd. Bispecific anti-HER2 antibody
US11858980B2 (en) 2016-08-02 2024-01-02 Visterra, Inc. Engineered polypeptides and uses thereof
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
WO2018148566A1 (en) * 2017-02-10 2018-08-16 Adimab, Llc Proteins binding bcma, nkg2d and cd16
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
US11938194B2 (en) 2017-02-28 2024-03-26 Seagen Inc. Cysteine mutated antibodies for conjugation
US11639394B2 (en) 2017-03-29 2023-05-02 Hoffmann-La Roche Inc. Bispecific antigen binding molecule for a costimulatory TNF receptor
US11242381B2 (en) 2017-04-21 2022-02-08 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
WO2018210795A1 (en) * 2017-05-16 2018-11-22 Synthon Biopharmaceuticals B.V. ANTI-SIRPα ANTIBODIES
US11718681B2 (en) 2017-05-16 2023-08-08 Byondis B.V. Anti-SIRP α antibodies
WO2018210793A3 (en) * 2017-05-16 2018-12-20 Synthon Biopharmaceuticals B.V. ANTI-SIRPα ANTIBODIES
US11274159B2 (en) 2017-05-16 2022-03-15 Byondis B.V. Anti-SIRPα antibodies
US11149094B2 (en) * 2017-06-05 2021-10-19 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
US20180346605A1 (en) * 2017-06-05 2018-12-06 Janssen Biotech, Inc. Engineered Multispecific Antibodies and Other Multimeric Proteins with Asymmetrical CH2-CH3 Region Mutations
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
US11248042B2 (en) 2017-10-31 2022-02-15 Staten Biotechnology B.V. Polynucleotides encoding anti-ApoC3 antibodies
US11248041B2 (en) 2017-10-31 2022-02-15 Staten Biotechnology B.V. Anti-ApoC3 antibodies
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US11939384B1 (en) 2018-02-08 2024-03-26 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
CN110082536A (zh) * 2019-04-17 2019-08-02 广州医科大学附属肿瘤医院 一种乳腺癌细胞标志物细胞因子群及其应用

Also Published As

Publication number Publication date
TW201817747A (zh) 2018-05-16
RU2743463C2 (ru) 2021-02-18
TW201400503A (zh) 2014-01-01
EP2857420A4 (en) 2015-12-30
JPWO2013180200A1 (ja) 2016-01-21
KR20200140404A (ko) 2020-12-15
KR20220092644A (ko) 2022-07-01
CN107759686A (zh) 2018-03-06
MX2021007663A (es) 2021-08-11
CA2874721A1 (en) 2013-12-05
CN107964042A (zh) 2018-04-27
HK1249530A1 (zh) 2018-11-02
JP2016106080A (ja) 2016-06-16
JP2023113713A (ja) 2023-08-16
US20190359704A1 (en) 2019-11-28
JP2018076374A (ja) 2018-05-17
JP7285891B2 (ja) 2023-06-02
DK2857420T3 (da) 2020-11-23
TWI797443B (zh) 2023-04-01
SG10202006507XA (en) 2020-08-28
CN104487457A (zh) 2015-04-01
US20230279099A1 (en) 2023-09-07
AU2020203710B2 (en) 2023-07-06
HK1245300A1 (zh) 2018-08-24
MX2014014678A (es) 2015-02-10
CN107964042B (zh) 2022-04-19
HK1205149A1 (en) 2015-12-11
KR20150016579A (ko) 2015-02-12
RU2014154067A (ru) 2016-07-20
EP2857420A1 (en) 2015-04-08
CN104487457B (zh) 2018-01-26
AU2020203710A1 (en) 2020-06-25
AU2018201358A1 (en) 2018-03-15
AU2013268418A1 (en) 2014-11-27
JP2020040975A (ja) 2020-03-19
JP2021181480A (ja) 2021-11-25
WO2013180200A1 (ja) 2013-12-05
AU2018201358B2 (en) 2020-03-19
EP3795215A1 (en) 2021-03-24
SG11201407963PA (en) 2015-01-29
TW202028252A (zh) 2020-08-01
TWI766939B (zh) 2022-06-11
AU2023229507A1 (en) 2023-09-28
JP6284517B2 (ja) 2018-02-28
JP6931034B2 (ja) 2021-09-01
AU2013268418B2 (en) 2017-12-07
EP2857420B1 (en) 2020-09-23
KR102413947B1 (ko) 2022-06-27
TWI617578B (zh) 2018-03-11
JP6663941B2 (ja) 2020-03-13
US11673947B2 (en) 2023-06-13

Similar Documents

Publication Publication Date Title
US11673947B2 (en) Target tissue-specific antigen-binding molecule
US11718678B2 (en) Method for altering plasma retention and immunogenicity of antigen-binding molecule
US11820793B2 (en) Drug containing carrier into cell for forming immune complex
US20220389118A1 (en) Antigen-binding molecule for promoting elimination of antigens
US20200115447A1 (en) Antigen-binding molecule inducing immune response to target antigen
AU2016277645B2 (en) Method for altering plasma retention and immunogenecity of antigen-binding molecule
US10961530B2 (en) Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
US20230257470A1 (en) Method for altering plasma retention and immunogenicity of antigen-binding molecule
US20240158785A1 (en) Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
CA2857159C (en) Drug containing carrier into cell for forming immune complex

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHUGAI SEIYAKU KABUSHIKI KAISHA, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IGAWA, TOMOYUKI;TAMBA, SHIGERO;TATSUMI, KANAKO;AND OTHERS;SIGNING DATES FROM 20150218 TO 20150224;REEL/FRAME:035399/0546

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION